The PD−1/PDL-1 pathway can prevent effective antitumor immunity by downregulating the function of CD8+ T lymphocytes, so ESCC patients who are PDL-1−positive have a poorer prognosis than negative patients (30). Here, CD274 is linked to esophageal squamous cell carcinoma.